Neurogene Inc. (NGNE)
Healthcare · NGM
Fundamentals
Valuation and ratings
Neurogene Inc. trades at USD37.34, which is 59% above the USD15.23 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 12 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
NGNE earnings and analyst estimates
Recommendation mix, 9 analyst ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
NGNE passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$7.80M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$4.13M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$874.9K · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$280.0K · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$207.9K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Is Neurogene Inc. (NGNE) undervalued?
Against our discounted cash flow estimate of USD15.23, NGNE at USD37.34 is 59% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
Which funds own NGNE?
5 of the institutions we track reported a position in NGNE in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
When does NGNE report earnings next?
Neurogene Inc. is scheduled to report on 11 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.
The full research page for NGNE, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.